Researchers at the US National Institute of Allergy and Infectious Diseases (NIAID) have studied the response of 34 adults, both young and old, from the first stage of the clinical trials.
In an article in the New England Journal of Medicine, they write that the antibodies decrease slowly over time, but they were still elevated in all participants three months after the second vaccine dose.
NIAID Director Anthony Fauci and other experts stress that the immune system will probably remember the virus and start producing new antibodies if it were to become infected again later.
— .
